CATX vs RARE · $280.6M cap vs rev $350.0M
Perspective Therapeutics Inc. (CATX) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Perspective Therapeutics Inc. (CATX) is a medical devices company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
CATX does not have a complete income-statement cache yet.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
CATX currently screens at market cap $280.6M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the CATX and RARE stock pages for the full models.
Not investment advice.